Neptune Wellness Solutions (NEPT) – Hot FDA News
-
Acasti Pharma (ACST) Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia Did Not Meet its Primary Endpoint
-
Acasti Pharma (ACST) Topline Results for TRILOGY 1 Phase 3 Trial of CaPre Postponed Due to Unexpected Delay in Data Processing and Transfer
Back to NEPT Stock Lookup
